Breaking News

Friday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
Amyris to host conference call » 16:24
04/16/21
04/16
16:24
04/16/21
16:24
AMRS

Amyris

$15.05 /

-0.66 (-4.20%)

Management holds an…

Management holds an investor update conference call on April 22 at 1 pm. Webcast Link

ShowHide Related Items >><<
AMRS Amyris
$15.05 /

-0.66 (-4.20%)

AMRS Amyris
$15.05 /

-0.66 (-4.20%)

03/03/21 Roth Capital
Amyris price target raised to $33 from $20 at Roth Capital
03/03/21 H.C. Wainwright
Amyris price target raised to $35 from $11 at H.C. Wainwright
02/26/21
Fly Intel: Top five analyst initiations
02/26/21 Roth Capital
Amyris initiated with a Buy at Roth Capital
AMRS Amyris
$15.05 /

-0.66 (-4.20%)

  • 09
    Apr
AMRS Amyris
$15.05 /

-0.66 (-4.20%)

AMRS Amyris
$15.05 /

-0.66 (-4.20%)

Thursday
Hot Stocks
Landec VP Hall buys 10K shares of company stock » 17:27
04/15/21
04/15
17:27
04/15/21
17:27
LNDC

Landec

$11.30 /

+0.73 (+6.91%)

Landec VP James Hall…

Landec VP James Hall disclosed in a filing that he had purchased 10,000 shares of company stock at $10.62 per share on April 14, for a total transaction cost of $106,200.

ShowHide Related Items >><<
LNDC Landec
$11.30 /

+0.73 (+6.91%)

LNDC Landec
$11.30 /

+0.73 (+6.91%)

04/08/21 Lake Street
Landec price target lowered to $12 from $13 at Lake Street
06/30/20
Fly Intel: Top five analyst downgrades
06/30/20 Lake Street
Landec price target raised to $11 after revenue beat at Lake Street
06/30/20 Barrington
Landec downgraded to Market Perform from Outperform at Barrington
LNDC Landec
$11.30 /

+0.73 (+6.91%)

LNDC Landec
$11.30 /

+0.73 (+6.91%)

LNDC Landec
$11.30 /

+0.73 (+6.91%)

Hot Stocks
Chinook Therapeutics presents data during ISN world congress, last four posters » 08:42
04/15/21
04/15
08:42
04/15/21
08:42
KDNY

Chinook Therapeutics

$13.79 /

-0.12 (-0.86%)

Chinook Therapeutics…

Chinook Therapeutics today announced six poster presentations at the ISN World Congress of Nephrology 2021. The final 4 posters include the following information. The third poster is titled "WCN21-0398: Human Renal Mesangial Cell Activation Induced by Endothelin-1 or IgA Nephropathy Patient Immune Derived Complexes is Blocked by Selective ETA Antagonist Atrasentan." Human renal mesangial cell activation is considered the initiating intra-renal event in the pathogenesis of IgAN and occurs in response to the deposition of pathogenic galactose-deficient IgA (Gd-IgA)-containing immune complexes. This activation results in increased cellular proliferation and inflammatory cytokine secretion. Exogenous ET-1 directly stimulates mesangial cell activation, inducing proliferative, pro-inflammatory and pro-fibrotic pathways, which can be blocked by atrasentan. Atrasentan prevented HRMC hyperproliferation in response to IgAN patient-derived immune complexes. This suggests that the autocrine action of endogenously produced ET-1 on ETA receptors contributes to mesangial cell activation resulting from pathogenic IgA-containing immune complexes. These results support the therapeutic potential of atrasentan in patients with IgAN, not only via its well characterized effect of reducing proteinuria, but also by potentially reducing mesangial cell activation, a hallmark of IgA nephropathy. Poster titled "WCN21-0848: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Atrasentan in Patients with IgA Nephropathy." The ALIGN Study is a global, randomized, multicenter, double-blind, placebo-controlled phase 3 clinical trial comparing the efficacy and safety of atrasentan versus placebo in patients with IgAN at risk of progressive loss of kidney function. Approximately 320 patients with biopsy-proven IgAN will be randomized to receive 0.75 mg atrasentan or placebo as a once-daily oral pill for approximately 2.5 years. The primary efficacy endpoint of the ALIGN Study is to evaluate the effect of atrasentan versus placebo on proteinuria as measured by urine protein to creatinine ratio from baseline to 24 weeks. Secondary and exploratory objectives include evaluating the change in kidney function over time as measured by eGFR, safety and tolerability, as well as quality of life. Chinook expects to report top-line data from the 24-week primary endpoint efficacy analysis in 2023. Poster titled "WCN21-0717: Atrasentan in Patients with Proteinuric Glomerular Diseases." The AFFINITY Study is a phase 2, open-label, basket study to evaluate the efficacy and safety of atrasentan in patients with proteinuric glomerular disease who are at risk of progressive loss of renal function. Four initial cohorts will consist of patients with: IgAN with UPCR of 0.5 to less than 1.0 g/g, focal segmental glomerulosclerosis, Approximately 20 patients will be enrolled in each cohort to receive 0.75 mg atrasentan for 52 weeks. Patients in all cohorts will continue receiving an optimized and stable dose of a RAS inhibitor as standard of care. The primary efficacy endpoint of the AFFINITY Study is the effect on proteinuria as measured by UPCR in patients with IgAN, FSGS and Alport syndrome and the change in albuminuria as measured by urine albumin to creatinine in patients with DKD, from baseline to 12 weeks. Chinook expects to report data from initial cohorts of patients in the AFFINITY Study during 2022. Poster titled "WCN21-0612: Discovery of CHK-336: A First-in-Class, Liver-Targeted, Small Molecule Inhibitor of Lactate Dehydrogenase for the Treatment of Hyperoxaluria." CHK-336, is a liver-targeted oral small molecule LDHA inhibitor for the treatment of PH. LDHA catalyzes the final step in the production of oxalate in the liver, and therefore LDHA inhibition has the potential to treat all forms of PH - PH1, PH2 and PH3 - as well as other disorders arising from excess oxalate. CHK-336 demonstrates tight LDHA binding and a very slow enzyme off-rate, to extend the duration of action and enable the potential of once-daily dosing in humans. CHK-336 was engineered with a liver-targeted distribution profile to effectively block hepatic oxalate synthesis while minimizing systemic exposures.

ShowHide Related Items >><<
KDNY Chinook Therapeutics
$13.79 /

-0.12 (-0.86%)

KDNY Chinook Therapeutics
$13.79 /

-0.12 (-0.86%)

04/05/21 H.C. Wainwright
Chinook spinoff 'prudent way' to maximize Aduro value, says H.C. Wainwright
03/30/21 Cantor Fitzgerald
Cantor says Chinook BION-1301 abstract suggests positive proof of concept
01/06/21
Fly Intel: Top five analyst initiations
01/06/21 Wedbush
Wedbush bullish on Chinook Therapeutics, initiates with an Outperform
KDNY Chinook Therapeutics
$13.79 /

-0.12 (-0.86%)

KDNY Chinook Therapeutics
$13.79 /

-0.12 (-0.86%)

KDNY Chinook Therapeutics
$13.79 /

-0.12 (-0.86%)

Hot Stocks
Chinook Therapeutics presents data during ISN world congress, first two posters » 08:42
04/15/21
04/15
08:42
04/15/21
08:42
KDNY

Chinook Therapeutics

$13.79 /

-0.12 (-0.86%)

Chinook Therapeutics…

Chinook Therapeutics today announced six poster presentations at the ISN World Congress of Nephrology 2021. The first two posters include the following information. The first poster is titled "WCN21-0706: A Phase 1, Open Label, Randomized, Single Dose, Parallel Group Safety and Bioavailability Study of BION-1301 Administered by Intravenous and Subcutaneous Routes," BION-1301 is a novel anti-APRIL monoclonal antibody currently in phase 1 clinical development for IgAN. Blocking APRIL is a potential disease-modifying approach to treating IgAN by reducing circulating levels of Gd-IgA1 to prevent the formation of immune complexes that deposit in the glomeruli of the kidney, causing damage. The ongoing phase 1 multi-center trial evaluated the safety and tolerability of BION-1301 in 63 healthy volunteers in double-blinded, placebo-controlled single-ascending dose, or SAD, and multiple-ascending dose, or MAD, settings. Recently analyzed data from this study in healthy volunteers demonstrated that BION-1301 produced dose-dependent reductions in serum Gd-IgA1 levels that were greater in magnitude than previously reported for total IgA concentrations. In the MAD cohort, BION-1301 reduced Gd-IgA1 levels by 39%, 51% and 55% on Day 29 following the first two doses but prior to the third dose of BION-1301 at 50 mg, 150 mg and 450 mg, respectively, compared to a mean 6% increase in Gd-IgA1 in the placebo group. Upon further follow-up on Day 85, which was 56 days after the third and final dose of BION-1301, Gd-IgA1 reductions were sustained, with mean reductions of 24%, 48% and 70%, at 50 mg, 150 mg and 450 mg, respectively, compared to a mean 4% increase in Gd-IgA1 in the placebo group. Part 3 of the phase 1 study is ongoing to evaluate BION-1301 in adult IgAN patients in an open-label setting. Preliminary data from Part 3 will be presented at nephrology conferences in 2021. Data generated in this study will be used to enable SC administration of BION-1301 in ongoing and future clinical studies. Poster titled "WCN21-0358: Selective ETA Antagonist Atrasentan, Rapidly Reduces Albuminuria and Downregulates Intra-renal Pro-Inflammatory and Pro-Fibrotic Transcriptional Networks in the g-ddY Mouse Model of Spontaneous IgA Nephropathy." The effect of short-term treatment of selective ETA antagonist atrasentan was investigated in gddY mice, a spontaneous and accelerated model of IgAN. Four days of treatment with atrasentan reduced urinary albumin to creatinine ratio from baseline by 28%, 62% and 63% at 10 mg/kg/day, 20 mg/kg/day and 30 mg/kg/day, respectively. This effect was statistically significant at the two higher doses. Five days of treatment with atrasentan demonstrated dose-dependent effects on intra-renal gene expression profiles, assessed by RNA sequencing analysis of the kidney cortex. The dynamic transcriptional changes in the kidney, following only five days of treatment and prior to sustained long-term reductions in albuminuria and blood pressure that could mediate this benefit, are consistent with direct anti-inflammatory and antifibrotic effects of ETA blockade in IgAN. These results support the therapeutic potential of atrasentan in IgAN to reduce proteinuria and kidney inflammation and fibrosis, key drivers of IgAN progression.

ShowHide Related Items >><<
KDNY Chinook Therapeutics
$13.79 /

-0.12 (-0.86%)

KDNY Chinook Therapeutics
$13.79 /

-0.12 (-0.86%)

04/05/21 H.C. Wainwright
Chinook spinoff 'prudent way' to maximize Aduro value, says H.C. Wainwright
03/30/21 Cantor Fitzgerald
Cantor says Chinook BION-1301 abstract suggests positive proof of concept
01/06/21
Fly Intel: Top five analyst initiations
01/06/21 Wedbush
Wedbush bullish on Chinook Therapeutics, initiates with an Outperform
KDNY Chinook Therapeutics
$13.79 /

-0.12 (-0.86%)

KDNY Chinook Therapeutics
$13.79 /

-0.12 (-0.86%)

KDNY Chinook Therapeutics
$13.79 /

-0.12 (-0.86%)

Hot Stocks
Amyris to acquire EcoFabulous Cosmetics, terms not disclosed » 08:03
04/15/21
04/15
08:03
04/15/21
08:03
AMRS

Amyris

$16.07 /

+0.71 (+4.62%)

Amyris announced that it…

Amyris announced that it has executed a binding term sheet for the acquisition of Gen Z-focused beauty brand, EcoFabulous Cosmetics. The acquisition furthers Amyris's growth and market leadership in clean beauty and complements Amyris's family of consumer brands, consisting of Biossance, Pipette, Rose Inc., JVN, Terasana, and Costa Brazil. Amyris is acquiring a 70% controlling interest in EcoFabulous and expects to grow the Gen Z consumer segment through Amyris's innovative science, sustainable ingredients, clean formulation and direct-to-consumer marketing expertise. Marissa will join Amyris to lead brand innovation and be the Chief Creative Officer for the EcoFabulous brand.

ShowHide Related Items >><<
AMRS Amyris
$16.07 /

+0.71 (+4.62%)

AMRS Amyris
$16.07 /

+0.71 (+4.62%)

03/03/21 Roth Capital
Amyris price target raised to $33 from $20 at Roth Capital
03/03/21 H.C. Wainwright
Amyris price target raised to $35 from $11 at H.C. Wainwright
02/26/21
Fly Intel: Top five analyst initiations
02/26/21 Roth Capital
Amyris initiated with a Buy at Roth Capital
AMRS Amyris
$16.07 /

+0.71 (+4.62%)

  • 09
    Apr
AMRS Amyris
$16.07 /

+0.71 (+4.62%)

AMRS Amyris
$16.07 /

+0.71 (+4.62%)

Wednesday
Hot Stocks
Amyris to acquire Beauty Labs, terms not disclosed » 08:02
04/14/21
04/14
08:02
04/14/21
08:02
AMRS

Amyris

$15.36 /

-0.19 (-1.22%)

Amyris announced that it…

Amyris announced that it has agreed to acquire Beauty Labs, an AI technology company that provides connected consumer experiences to the beauty and wellness community. The parties expect to sign a definitive agreement and close over the next 30 days subject to the successful completion of due diligence and customary closing conditions.

ShowHide Related Items >><<
AMRS Amyris
$15.36 /

-0.19 (-1.22%)

AMRS Amyris
$15.36 /

-0.19 (-1.22%)

03/03/21 Roth Capital
Amyris price target raised to $33 from $20 at Roth Capital
03/03/21 H.C. Wainwright
Amyris price target raised to $35 from $11 at H.C. Wainwright
02/26/21
Fly Intel: Top five analyst initiations
02/26/21 Roth Capital
Amyris initiated with a Buy at Roth Capital
AMRS Amyris
$15.36 /

-0.19 (-1.22%)

  • 09
    Apr
AMRS Amyris
$15.36 /

-0.19 (-1.22%)

AMRS Amyris
$15.36 /

-0.19 (-1.22%)

Initiation
AVCtechnologies initiated with a Buy at Loop Capital » 06:39
04/14/21
04/14
06:39
04/14/21
06:39
AVCT

AVCtechnologies

$8.00 /

+0.01 (+0.13%)

Loop Capital analyst Yun…

Loop Capital analyst Yun Kim initiated coverage of AVCtechnologies with a Buy rating and $17 price target. The company offers the "right technology, right growth strategy, right partnership and right management" to capture "at least" a niche market share in a fast-growing cloud communications market that should be growing in the low-teens or more CAGR over the next five years to $78B, the analyst tells investors in a research note. Kim adds that the current AVCtechnologies share price provides a "compelling risk/reward profile".

ShowHide Related Items >><<
AVCT AVCtechnologies
$8.00 /

+0.01 (+0.13%)

AVCT AVCtechnologies
$8.00 /

+0.01 (+0.13%)

04/14/21 Loop Capital
AVCtechnologies initiated with a Buy at Loop Capital
04/08/21 Northland
Ribbon could see 'healthy return' on Kandy if AVC sold, says Northland
AVCT AVCtechnologies
$8.00 /

+0.01 (+0.13%)

AVCT AVCtechnologies
$8.00 /

+0.01 (+0.13%)

Initiation
AVCtechnologies initiated with a Buy at Loop Capital » 06:33
04/14/21
04/14
06:33
04/14/21
06:33
AVCT

AVCtechnologies

$8.00 /

+0.01 (+0.13%)

Loop Capital analyst Yun…

Loop Capital analyst Yun Kim initiated coverage of AVCtechnologies with a Buy rating and $17 price target.

ShowHide Related Items >><<
AVCT AVCtechnologies
$8.00 /

+0.01 (+0.13%)

AVCT AVCtechnologies
$8.00 /

+0.01 (+0.13%)

04/08/21 Northland
Ribbon could see 'healthy return' on Kandy if AVC sold, says Northland
AVCT AVCtechnologies
$8.00 /

+0.01 (+0.13%)

AVCT AVCtechnologies
$8.00 /

+0.01 (+0.13%)

Tuesday
Recommendations
Otonomy price target raised to $6 from $5 at Piper Sandler » 04:52
04/13/21
04/13
04:52
04/13/21
04:52
OTIC

Otonomy

$2.21 /

-0.015 (-0.67%)

Piper Sandler analyst…

Piper Sandler analyst Christopher Raymond raised the firm's price target on Otonomy to $6 from $5 and keeps an Overweight rating on the shares. The analyst likes the risk/reward at current share levels and is a buyer approaching $6 per share. While the Phase 3 failure of Otividex this past February represented a setback for the company, current share levels reflect "little if any value for a full pipeline of targeted agents for the ear," two of which have already demonstrated proof of concept efficacy with additional validating readouts expected mid-2022, Raymond tells investors in a research note. With shares trading at a discount to peers, the setup is favorable for Otonomy, says the analyst.

ShowHide Related Items >><<
OTIC Otonomy
$2.21 /

-0.015 (-0.67%)

OTIC Otonomy
$2.21 /

-0.015 (-0.67%)

02/22/21 Piper Sandler
Otonomy price target lowered to $5 from $10 at Piper Sandler
12/18/20 H.C. Wainwright
Otonomy price target raised to $10 from $9 at H.C. Wainwright
12/17/20 Piper Sandler
Piper says Otonomy's OTO-413 appears active, peak sales 'not accounted for'
11/04/20 Piper Sandler
Piper Sandler likes risk/reward on Otonomy ahead of two readouts by year-end
OTIC Otonomy
$2.21 /

-0.015 (-0.67%)

  • 08
    Apr
  • 09
    Jul
OTIC Otonomy
$2.21 /

-0.015 (-0.67%)

Over a week ago
On The Fly
Fly Intel: After-Hours Movers » 18:25
04/12/21
04/12
18:25
04/12/21
18:25
MFNC

Mackinac Financial

$13.26 /

-0.23 (-1.70%)

, RILY

B. Riley Financial

$60.92 /

-0.51 (-0.83%)

, OTIC

Otonomy

$2.21 /

-0.015 (-0.67%)

, ZUO

Zuora

$16.48 /

+0.045 (+0.27%)

, SLP

Simulations Plus

$63.41 /

+1.45 (+2.34%)

, FBIO

Fortress Biotech

$5.47 /

+0.02 (+0.37%)

, NI

NiSource

$24.74 /

+0.045 (+0.18%)

, SCKT

Socket Mobile

$7.17 /

-0.69 (-8.78%)

, CHWY

Chewy

$84.02 /

+0.03 (+0.04%)

ShowHide Related Items >><<
ZUO Zuora
$16.48 /

+0.045 (+0.27%)

SLP Simulations Plus
$63.41 /

+1.45 (+2.34%)

SCKT Socket Mobile
$7.17 /

-0.69 (-8.78%)

RILY B. Riley Financial
$60.92 /

-0.51 (-0.83%)

OTIC Otonomy
$2.21 /

-0.015 (-0.67%)

NI NiSource
$24.74 /

+0.045 (+0.18%)

MFNC Mackinac Financial
$13.26 /

-0.23 (-1.70%)

FBIO Fortress Biotech
$5.47 /

+0.02 (+0.37%)

CHWY Chewy
$84.02 /

+0.03 (+0.04%)

MFNC Mackinac Financial
$13.26 /

-0.23 (-1.70%)

RILY B. Riley Financial
$60.92 /

-0.51 (-0.83%)

OTIC Otonomy
$2.21 /

-0.015 (-0.67%)

02/22/21 Piper Sandler
Otonomy price target lowered to $5 from $10 at Piper Sandler
12/18/20 H.C. Wainwright
Otonomy price target raised to $10 from $9 at H.C. Wainwright
12/17/20 Piper Sandler
Piper says Otonomy's OTO-413 appears active, peak sales 'not accounted for'
11/04/20 Piper Sandler
Piper Sandler likes risk/reward on Otonomy ahead of two readouts by year-end
ZUO Zuora
$16.48 /

+0.045 (+0.27%)

04/08/21 Berenberg
Zuora initiated with a Buy at Berenberg
02/24/21 Jefferies
Zuora price target raised to $17 from $13 at Jefferies
12/04/20 Canaccord
Zuora risk/reward attractive into next year, says Canaccord
06/29/20 Goldman Sachs
Zuora price target raised to $11 from $10 at Goldman Sachs
SLP Simulations Plus
$63.41 /

+1.45 (+2.34%)

01/12/21
Fly Intel: Top five analyst downgrades
01/12/21 Craig-Hallum
Simulations Plus downgraded to Hold from Buy at Craig-Hallum
01/12/21 Oppenheimer
Simulations Plus price target raised to $85 from $79 at Oppenheimer
11/25/20 Taglich Brothers
Simulations Plus upgraded to Buy from Speculative Buy at Taglich Brothers
FBIO Fortress Biotech
$5.47 /

+0.02 (+0.37%)

04/05/21 B. Riley
Fortress Biotech price target raised to $9 from $8 at B. Riley
02/17/21 Dawson James
Fortress Biotech price target raised to $21 from $16 at Dawson James
12/14/20 Benchmark
Decision looms on Fortress' Caelum after partner Alexion bought, says Benchmark
10/13/20 B. Riley
Fortress Biotech weakness on Avenue CRL overblown, says B. Riley Securities
NI NiSource
$24.74 /

+0.045 (+0.18%)

03/22/21 UBS
NiSource upgraded to Buy from Neutral at UBS
01/28/21 Goldman Sachs
NiSource downgraded to Neutral from Buy at Goldman Sachs
11/18/20 Barclays
NiSource upgraded to Overweight from Equal Weight at Barclays
10/19/20 BofA
NiSource upgraded to Buy from Neutral at BofA
SCKT Socket Mobile
$7.17 /

-0.69 (-8.78%)

CHWY Chewy
$84.02 /

+0.03 (+0.04%)

04/05/21 Evercore ISI
Chewy assumed with an Outperform at Evercore ISI
03/31/21 Wolfe Research
Chewy initiated with a Peer Perform at Wolfe Research
03/31/21 Wedbush
Chewy price target raised to $100 from $90 at Wedbush
03/31/21 Jefferies
Chewy price target raised to $105 from $100 at Jefferies
ZUO Zuora
$16.48 /

+0.045 (+0.27%)

SLP Simulations Plus
$63.41 /

+1.45 (+2.34%)

SCKT Socket Mobile
$7.17 /

-0.69 (-8.78%)

RILY B. Riley Financial
$60.92 /

-0.51 (-0.83%)

OTIC Otonomy
$2.21 /

-0.015 (-0.67%)

NI NiSource
$24.74 /

+0.045 (+0.18%)

FBIO Fortress Biotech
$5.47 /

+0.02 (+0.37%)

CHWY Chewy
$84.02 /

+0.03 (+0.04%)

  • 20
    Apr
  • 08
    Apr
  • 13
    Jan
  • 17
    Sep
  • 06
    Aug
  • 09
    Jul
CHWY Chewy
$84.02 /

+0.03 (+0.04%)

ZUO Zuora
$16.48 /

+0.045 (+0.27%)

SCKT Socket Mobile
$7.17 /

-0.69 (-8.78%)

RILY B. Riley Financial
$60.92 /

-0.51 (-0.83%)

OTIC Otonomy
$2.21 /

-0.015 (-0.67%)

CHWY Chewy
$84.02 /

+0.03 (+0.04%)

ZUO Zuora
$16.48 /

+0.045 (+0.27%)

SLP Simulations Plus
$63.41 /

+1.45 (+2.34%)

FBIO Fortress Biotech
$5.47 /

+0.02 (+0.37%)

CHWY Chewy
$84.02 /

+0.03 (+0.04%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.